Version history

{
  "session_id": "sess_SDA-2026-04-07-gap-debate-20260406-062039-7ef9980b_task_9aae8fc5",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "scidex.core.llm.complete",
  "action": "synthesize",
  "content": "{\"ranked_hypotheses\":[{\"title\":\"HDAC2 Phospho-Lock Window for Synaptic Gene Silencing\",\"description\":\"A narrow pre-symptomatic window exists (CDR 0) when HDAC2 enrichment at synaptic gene promoters remains reversible. Aβ oligomer-triggered CK2/Glutamate receptor signaling phosphorylates HDAC2 at S421/S423, locking it at chromatin before cognitive symptoms emerge. Intervention via HDAC2-selective inhibitors or CK2 inhibition during this window restores synaptic plasticity gene expression.\",\"target_gene\":\"HDAC2 (phospho-S421)\",\"dimension_scores\":{\"evidence_strength\":0.72,\"novelty\":0.68,\"feasibility\":0.58,\"therapeutic_potential\":0.65,\"mechanistic_plausibility\":0.62,\"druggability\":0.60,\"safety_profile\":0.55,\"competitive_landscape\":0.70,\"data_availability\":0.65,\"reproducibility\":0.68},\"composite_score\":0.643,\"evidence_for\":[{\"claim\":\"HDAC2 overexpression impairs synaptic plasticity and memory\",\"pmid\":\"22683681\"},{\"claim\":\"HDAC2 phosphorylation at S421/S423 by CK2 mediates synaptic gene silencing\",\"pmid\":\"33472075\"},{\"claim\":\"HDAC2-selective inhibitor reverses deficits in 3xTg AD mice\",\"pmid\":\"34358343\"}],\"evidence_against\":[{\"claim\":\"HDAC2-45 compound lacks confirmed isozyme selectivity via ABPP\",\"pmid\":\"34358343\"},{\"claim\":\"CK2 elevation in human AD neurons not directly demonstrated\",\"pmid\":\"33472075\"},{\"claim\":\"HDAC2 reduction improves memory even in adult mice with established pathology\",\"pmid\":\"22683681\"}]},{\"title\":\"HDAC3-Dependent A1 Astrocyte Commitment Window\",\"description\":\"Reactive astrocytes transition from neuroprotective A2 to neurotoxic A1 state through HDAC3-dependent epigenetic silencing of neuroprotective genes (SLC2A4, SDH) and induction of complement genes (C3, C4a). This commitment is reversible only during the first 4-6 weeks post-Aβ exposure; beyond this, chromatin becomes permanently altered through Polycomb-mediated H3K27me3 deposition.\",\"target_gene\":\"HDAC3\",\"dimension_scores\":{\"evidence_strength\":0.65,\"novelty\":0.62,\"feasibility\":0.55,\"therapeutic_potential\":0.60,\"mechanistic_plausibility\":0.58,\"druggability\":0.58,\"safety_profile\":0.50,\"competitive_landscape\":0.65,\"data_availability\":0.58,\"reproducibility\":0.60},\"composite_score\":0.611,\"evidence_for\":[{\"claim\":\"Astrocyte HDAC3 drives neuroinflammatory gene expression\",\"pmid\":\"34170622\"},{\"claim\":\"C3+ astrocytes correlate with neurodegeneration in AD\",\"pmid\":\"30626859\"},{\"claim\":\"KDM6B/JMJD3 promotes A2 astrocyte phenotype\",\"pmid\":\"35220457\"}],\"evidence_against\":[{\"claim\":\"GFAP elevation non-specific to A1/A2 transition\",\"pmid\":\"34170622\"},{\"claim\":\"No living-patient assay for astrocyte epigenetic commitment exists\",\"pmid\":\"34170622\"},{\"claim\":\"HDAC3 inhibition may affect neurons and microglia systemically\",\"pmid\":\"34170622\"}]},{\"title\":\"DNMT1 Compensation Window During Synaptic Resilience Phase\",\"description\":\"During early amyloid nucleation (Braak I-II), compensatory DNMT1 upregulation maintains BDNF promoter methylation and synaptic gene expression. This compensation fails at a specific transition point marked by CSF p-tau217/181 elevation, after which DNMT1 activity becomes irreversibly dysregulated. Restoration before this window preserves synaptic resilience.\",\"target_gene\":\"DNMT1\",\"dimension_scores\":{\"evidence_strength\":0.60,\"novelty\":0.70,\"feasibility\":0.42,\"therapeutic_potential\":0.58,\"mechanistic_plausibility\":0.52,\"druggability\":0.38,\"safety_profile\":0.35,\"competitive_landscape\":0.60,\"data_availability\":0.55,\"reproducibility\":0.58},\"composite_score\":0.528,\"evidence_for\":[{\"claim\":\"DNMT1 activity declines in AD prefrontal cortex\",\"pmid\":\"20843882\"},{\"claim\":\"Aβ oligomers suppress DNMT1 activity via calpain cleavage\",\"pmid\":\"31311445\"},{\"claim\":\"BDNF promoter hypermethylation correlates with cognitive decline\",\"pmid\":\"30631652\"}],\"evidence_against\":[{\"claim\":\"DNMT1 lacks known small-molecule activators\",\"pmid\":\"31311445\"},{\"claim\":\"DNMT1 upregulation is oncogenic - global activation risks carcinogenesis\",\"pmid\":\"20843882\"},{\"claim\":\"p-tau elevation causation for DNMT1 failure not established\",\"pmid\":\"31311445\"}]},{\"title\":\"Circadian Clock Epigenetic Desynchronization Window\",\"description\":\"During preclinical AD, BMAL1 promoter hypermethylation disrupts circadian epigenetic rhythms in neurons and astrocytes, leading to desynchronization of metabolic and inflammatory gene expression. This window is uniquely targetable because circadian enhancement via HDAC inhibitors shows maximal efficacy during specific circadian phases (zeitgeber time 8-12).\",\"target_gene\":\"BMAL1/HDAC3\",\"dimension_scores\":{\"evidence_strength\":0.52,\"novelty\":0.72,\"feasibility\":0.48,\"therapeutic_potential\":0.52,\"mechanistic_plausibility\":0.50,\"druggability\":0.52,\"safety_profile\":0.48,\"competitive_landscape\":0.55,\"data_availability\":0.45,\"reproducibility\":0.50},\"composite_score\":0.524,\"evidence_for\":[{\"claim\":\"BMAL1 is hypermethylated in AD entorhinal cortex\",\"pmid\":\"28829138\"},{\"claim\":\"HDAC3 inhibition restores circadian gene expression\",\"pmid\":\"30782526\"},{\"claim\":\"Circadian disruption accelerates amyloid clearance impairment\",\"pmid\":\"29034197\"}],\"evidence_against\":[{\"claim\":\"BMAL1 is a transcription factor - direct targeting low feasibility\",\"pmid\":\"28829138\"},{\"claim\":\"Sleep fragmentation non-specific to AD circadian disruption\",\"pmid\":\"29034197\"},{\"claim\":\"Circadian phase-dependent dosing raises compliance challenges\",\"pmid\":\"30782526\"}]},{\"title\":\"TREM2 Epigenetic Window for Microglial Lipid Metabolism\",\"description\":\"TREM2 p-T323 phosphorylation by SYK/HS1 kinase shifts microglial epigenetic programming toward lipid droplet accumulation and cholesterol dysregulation. HDAC1 recruitment to lipid metabolism genes (Abca1, Abcg1, Lpl) during this window creates a TREM2-dependent feedback loop that, if interrupted early, prevents foam cell formation and inflammatory escalation.\",\"target_gene\":\"TREM2/HDAC1\",\"dimension_scores\":{\"evidence_strength\":0.55,\"novelty\":0.65,\"feasibility\":0.45,\"therapeutic_potential\":0.52,\"mechanistic_plausibility\":0.48,\"druggability\":0.45,\"safety_profile\":0.50,\"competitive_landscape\":0.58,\"data_availability\":0.52,\"reproducibility\":0.55},\"composite_score\":0.525,\"evidence_for\":[{\"claim\":\"TREM2 p-T323 is activated by Aβ and lipids\",\"pmid\":\"33372140\"},{\"claim\":\"TREM2-deficient microglia accumulate lipid droplets\",\"pmid\":\"29995688\"},{\"claim\":\"HDAC1 represses ABCA1 in foam cells\",\"pmid\":\"30639346\"}],\"evidence_against\":[{\"claim\":\"HDAC1 activators are pharmacologically unprecedented\",\"pmid\":\"30639346\"},{\"claim\":\"CSF sTREM2 reflects cleavage, not phosphorylation status\",\"pmid\":\"33372140\"},{\"claim\":\"LDL/HDL ratio not AD-specific\",\"pmid\":\"29995688\"}]},{\"title\":\"α-Ketoglutarate/2-HG Metabolic-Epigenetic Window in Neurons\",\"description\":\"Mitochondrial dysfunction in early AD causes accumulation of 2-hydroxyglutarate (2-HG), an oncometabolite that inhibits α-KG-dependent JMJC histone demethylases (KDM4B, KDM5B). This creates a histone methylation traffic jam particularly affecting H3K9me3 at repetitive elements and H3K27me3 at developmental genes, altering neuronal transcriptomes before amyloid pathology peaks.\",\"target_gene\":\"2-HG/KDM4B\",\"dimension_scores\":{\"evidence_strength\":0.45,\"novelty\":0.68,\"feasibility\":0.35,\"therapeutic_potential\":0.48,\"mechanistic_plausibility\":0.38,\"druggability\":0.32,\"safety_profile\":0.40,\"competitive_landscape\":0.50,\"data_availability\":0.42,\"reproducibility\":0.45},\"composite_score\":0.443,\"evidence_for\":[{\"claim\":\"2-HG accumulates in AD brain and correlates with cognitive decline\",\"pmid\":\"31408041\"},{\"claim\":\"KDM4B regulates amyloid processing genes\",\"pmid\":\"36914825\"},{\"claim\":\"α-KG supplementation restores JMJC demethylase activity in aging\",\"pmid\":\"33571436\"}],\"evidence_against\":[{\"claim\":\"Mutant IDH-like activity source undefined and unproven\",\"pmid\":\"31408041\"},{\"claim\":\"2-HG accumulation shared with ischemic injury and mitochondrial disorders\",\"pmid\":\"31408041\"},{\"claim\":\"α-KG supplementation has poor CNS penetration\",\"pmid\":\"33571436\"}]},{\"title\":\"Microglial Priming Window for HDAC1-Dependent DAM Transition\",\"description\":\"During early amyloid deposition, a transient window exists where microglia exist in a primed state characterized by HDAC1-mediated silencing of P2RY12/TMEM119 and gradual upregulation of disease-associated microglia (DAM) genes (Trem2, Tyrobp, Apoe). Intervention during this window prevents full DAM commitment and maintains neuroprotective surveillance.\",\"target_gene\":\"HDAC1\",\"dimension_scores\":{\"evidence_strength\":0.52,\"novelty\":0.62,\"feasibility\":0.38,\"therapeutic_potential\":0.50,\"mechanistic_plausibility\":0.40,\"druggability\":0.32,\"safety_profile\":0.38,\"competitive_landscape\":0.55,\"data_availability\":0.48,\"reproducibility\":0.48},\"composite_score\":0.463,\"evidence_for\":[{\"claim\":\"Microglial HDAC1 activity increases in 5xFAD mice at 3-4 months\",\"pmid\":\"36747023\"},{\"claim\":\"Trem2 loss-of-function prevents DAM transition\",\"pmid\":\"29539578\"},{\"claim\":\"HDAC3 inhibition promotes microglial anti-inflammatory phenotype\",\"pmid\":\"35034217\"}],\"evidence_against\":[{\"claim\":\"Internal contradiction: HDAC1 inhibition vs HDAC3 activation incompatible mechanisms\",\"pmid\":\"36747023\"},{\"claim\":\"HDAC1-selective inhibitors do not exist\",\"pmid\":\"36747023\"},{\"claim\":\"CSF sTREM2 cannot distinguish priming from committed DAM states\",\"pmid\":\"29539578\"}]}],\"knowledge_edges\":[{\"source_id\":\"H2\",\"source_type\":\"hypothesis\",\"target_id\":\"HDAC2\",\"target_type\":\"gene\",\"relation\":\"primary_therapeutic_target\"},{\"source_id\":\"H2\",\"source_type\":\"hypothesis\",\"target_id\":\"CK2\",\"target_type\":\"kinase\",\"relation\":\"upstream_regulator_of_HDAC2_phosphorylation\"},{\"source_id\":\"H5\",\"source_type\":\"hypothesis\",\"target_id\":\"HDAC3\",\"target_type\":\"gene\",\"relation\":\"primary_therapeutic_target\"},{\"source_id\":\"H5\",\"source_type\":\"hypothesis\",\"target_id\":\"C3\",\"target_type\":\"protein\",\"relation\":\"downstream_A1_astrocyte_marker\"},{\"source_id\":\"H1\",\"source_type\":\"hypothesis\",\"target_id\":\"DNMT1\",\"target_type\":\"enzyme\",\"relation\":\"primary_therapeutic_target\"},{\"source_id\":\"H1\",\"source_type\":\"hypothesis\",\"target_id\":\"BDNF\",\"target_type\":\"gene\",\"relation\":\"downstream_synaptic_target\"},{\"source_id\":\"H3\",\"source_type\":\"hypothesis\",\"target_id\":\"HDAC1\",\"target_type\":\"gene\",\"relation\":\"contradictory_therapeutic_target\"},{\"source_id\":\"H3\",\"source_type\":\"hypothesis\",\"target_id\":\"HDAC3\",\"target_type\":\"gene\",\"relation\":\"alternative_therapeutic_target_unclear\"},{\"source_id\":\"H4\",\"source_type\":\"hypothesis\",\"target_id\":\"2-HG\",\"target_type\":\"metabolite\",\"relation\":\"undefined_source_enzyme\"},{\"source_id\":\"H4\",\"source_type\":\"hypothesis\",\"target_id\":\"KDM4B\",\"target_type\":\"demethylase\",\"relation\":\"inhibited_by_2-HG\"},{\"source_id\":\"H6\",\"source_type\":\"hypothesis\",\"target_id\":\"TREM2\",\"target_type\":\"receptor\",\"relation\":\"upstream_regulator\"},{\"source_id\":\"H6\",\"source_type\":\"hypothesis\",\"target_id\":\"ABCA1\",\"target_type\":\"transporter\",\"relation\":\"repressed_by_HDAC1\"},{\"source_id\":\"H7\",\"source_type\":\"hypothesis\",\"target_id\":\"BMAL1\",\"target_type\":\"transcription_factor\",\"relation\":\"epigenetically_dysregulated\"},{\"source_id\":\"H7\",\"source_type\":\"hypothesis\",\"target_id\":\"HDAC3\",\"target_type\":\"enzyme\",\"relation\":\"therapeutic_modulator\"},{\"source_id\":\"H1\",\"source_type\":\"hypothesis\",\"target_id\":\"CSF_p-tau217\",\"target_type\":\"biomarker\",\"relation\":\"proposed_transition_point_marker_circular\"},{\"source_id\":\"H2\",\"source_type\":\"hypothesis\",\"target_id\":\"CSF_p-tau\",\"target_type\":\"biomarker\",\"relation\":\"synaptic_tau_correlate\"}],\"synthesis_summary\":\"The debate identified a critical biomarker translation barrier across all seven hypotheses: the therapeutic windows cannot be reliably identified in living patients. The proposed biomarkers (CSF p-tau, amyloid PET, GFAP, sleep fragmentation) are either non-specific to the epigenetic mechanism, technically unmeasurable in vivo (chromatin states require brain tissue), or represent indirect correlates rather than causal indicators of epigenetic dysregulation. Only Hypothesis 2 (HDAC2) and Hypothesis 5 (Astrocyte HDAC3) warrant prioritized investment, as both have pharmacological tractability (HDAC2-selective inhibitors and CK2 inhibitors for H2; RGFP966 and HDAC3 inhibitors for H5) and feasible experimental validation pathways. The remaining hypotheses suffer from fundamental barriers: undefined drug targets (H4), mechanistic contradictions (H3), unacceptable safety profiles (H1 oncogenic risk), or lack of patient stratification biomarkers. The optimal therapeutic window appears to be approximately 12-18 months before clinical symptom onset (CDR 0 to 0.5 transition) corresponding to amyloid PET positivity with normal tau PET, though this temporal specificity cannot currently be matched to specific epigenetic states in living patients.\"}",
  "tokens_used": "3180",
  "persona_id": "persona-synthesizer"
}